;
Skip to main content
Home > The Daily Extra > Company News

Chronological Index of : Company News

 Current Issue
  • COMPANY NEWS: FDA approves Pfizer's meningitis B vaccine

    FDA granted accelerated approval for Trumenba from Pfizer Inc. (NYSE:PFE) to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B in individuals aged 10-25. The bivalent meningococcal B …

    Published on 10/29/2014
  • COMPANY NEWS: Xencor revises XmAb5871 deal with Amgen

    Xencor Inc. (NASDAQ:XNCR) renegotiated its deal with Amgen Inc. (NASDAQ:AMGN) related to autoimmune candidate XmAb5871. Xencor terminated the companies' original deal in which the bellwether had an option to license …

    Published on 10/29/2014
  • COMPANY NEWS: Amgen committed to pipeline, not breakup

    Amgen Inc. (NASDAQ:AMGN) shares traded up $8.99 to $157.19 on Tuesday after it mapped out its growth strategy at its investor meeting and said it has no intention to break up.Amgen is under pressure from activist …

    Published on 10/28/2014
  • COMPANY NEWS: Big gain for Receptos on UC data

    Receptos Inc. (NASDAQ:RCPT) jumped $28.02 (41%) to $95.76 on Tuesday, building its market cap to $2.6 billion, following disclosure after market on Monday that RPC1063 met the primary endpoint in the 199-patient Phase …

    Published on 10/28/2014
  • COMPANY NEWS: BMS takes option to acquire F-star Alpha

    Bristol-Myers Squibb Co. (NYSE:BMY) obtained an exclusive option to acquire F-star Alpha Ltd. (Cambridge, U.K.). The Cambridge-based F-star Biotechnology Ltd subsidiary of F-star GmbH (Vienna, Austria) spun out F-star …

    Published on 10/28/2014
  • COMPANY NEWS: FDA reviewers question advantages of edoxaban

    FDA reviewers said the agency normally would issue a complete response for Savaysa edoxaban from Daiichi Sankyo Co. Ltd. (Tokyo:4568) to prevent stroke and systemic embolism in patients with non-valvular atrial …

    Published on 10/28/2014
  • COMPANY NEWS: New deals for J&J's Asia-Pacific Innovation Center

    Johnson & Johnson (NYSE:JNJ) launched its Asia Pacific Innovation Center, the fourth of J&J's centers. Located in Shanghai with satellite offices in Singapore, Australia and Japan, the center will identify early stage …

    Published on 10/28/2014
  • COMPANY NEWS: TMC jumps after court upholds Angiomax patent

    The Medicines Co. (NASDAQ:MDCO) jumped $3.67 (17%) to $25.86 on Tuesday after the U.S. District Court for the Northern District of Illinois ruled that an ANDA filed by Mylan Inc. (NASDAQ:MYL) seeking approval of a …

    Published on 10/28/2014
  • COMPANY NEWS: Triphase signs cancer pacts with Celgene, PharmAbcine

    As part of a three-way deal, Triphase Accelerator Corp. (San Diego, Calif.) in-licensed global rights excluding China and Korea to preclinical oncology candidate TRPH 011 from PharmAbcine Inc. (Daejon, South Korea). …

    Published on 10/28/2014
  • COMPANY NEWS: Akebia slides on HIF inhibitor's SAEs

    Akebia Therapeutics Inc. (NASDAQ:AKBA) fell $5.75 (29%) to $13.97 on Monday after data from a Phase IIb trial of its AKB-6548 to treat anemia associated with chronic kidney disease (CKD) showed an increase in serious …

    Published on 10/27/2014
  • COMPANY NEWS: CSL gives Novartis a better deal for flu vaccines

    CSL Ltd. (ASX:CSL) will acquire the influenza vaccines business of Novartis AG (NYSE:NVS; SIX:NOVN) for $275 million, more than the Swiss pharma would have collected by exercising its right to put the assets to …

    Published on 10/27/2014
  • COMPANY NEWS: Express Scripts CMO: Harvoni 'price is wrong'

    Express Scripts Holding Co. (NASDAQ:ESRX) CMO Steven Miller compared the price of Harvoni sofosbuvir/ledipasvir from Gilead Sciences Inc. (NASDAQ:GILD) with expensive Orphan drugs in a blog post, calling the price "…

    Published on 10/27/2014
  • COMPANY NEWS: Pain, Durect slammed as Pfizer abandons Remoxy

    Shares of Pain Therapeutics Inc. (NASDAQ:PTIE) and Durect Corp. (NASDAQ:DRRX) plummeted on Monday after Pfizer Inc. (NYSE:PFE) decided to discontinue development of Remoxy oxycodone, which is designed to be abuse-…

    Published on 10/27/2014
  • COMPANY NEWS: Sanofi says board not discussing Viehbacher ouster

    Sanofi (Euronext:SAN; NYSE:SNY) contradicted press reports that its board of directors planned to discuss ousting CEO Chris Viebacher at a meeting on Monday. "[T]his ordinary Board meeting is mainly dedicated to the …

    Published on 10/27/2014
  • COMPANY NEWS: Sarepta plummets on eteplirsen NDA delay

    Sarepta Therapeutics Inc. (NASDAQ:SRPT) fell $7.65 (32%) to $15.91 on Monday after saying it would delay its NDA submission for eteplirsen (AVI-4658) to treat Duchenne muscular dystrophy (DMD) to mid-2015. In July, the …

    Published on 10/27/2014
  • COMPANY NEWS: Baxter's Rixubis gets CHMP nod for hemophilia B

    EMA's CHMP recommended marketing authorization of Rixubis (BAX 326) from Baxter International Inc. (NYSE:BAX) to treat and prevent bleeding in patients with hemophilia B. Approval will include a pharmacovigilance plan.…

    Published on 10/24/2014
  • COMPANY NEWS: CHMP recommends Clinuvel's Scenesse

    EMA's CHMP recommended marketing authorization under exceptional circumstances for Scenesse afamelanotide from Clinuvel Pharmaceuticals Ltd. (ASX:CUV; Xetra:UR9) to treat phototoxicity in patients with erythropoietic …

    Published on 10/24/2014
  • COMPANY NEWS: CHMP wants more warnings for Ariad's Iclusig

    EMA's CHMP recommended stronger warnings concerning risks of blood clots and arterial blockage with use of leukemia drug Iclusig ponatinib from Ariad Pharmaceuticals Inc. (NASDAQ:ARIA). CHMP's opinion endorses a similar…

    Published on 10/24/2014
  • COMPANY NEWS: Unlike FDA panel, CHMP backs AZ's olaparib

    EMA's CHMP recommended marketing authorization of Lynparza olaparib from AstraZeneca plc (LSE:AZN; NYSE:AZN) as maintenance treatment of platinum-sensitive relapsed ovarian, fallopian tube or peritoneal cancer in …

    Published on 10/24/2014
  • COMPANY NEWS: Venture Tracks

    PureTech Ventures (Boston, Mass.) named Robert Horvitz, Joi Ito and Raju Kucherlapati as senior partners. Horvitz, a Nobel Laureate, is a professor at Massachusetts Institute of Technology and a co-founder of Epizyme …

    Published on 10/24/2014
  • COMPANY NEWS: Celgene takes option in Sutro cancer deal

    Celgene Corp. (NASDAQ:CELG) paid Sutro Biopharma Inc. (South San Francisco, Calif.) $95 million up front in a deal to develop cancer immunotherapies using Sutro's cell-free protein synthesis technology. Celgene also …

    Published on 10/23/2014
  • COMPANY NEWS: FDA pushes back Natpara PDUFA

    NPS Pharmaceuticals Inc. (NASDAQ:NPSP) said FDA has delayed the PDUFA date for Natpara from Oct. 24 to Jan. 24, 2015, to review a major amendment to the BLA. NPS said the agency has also asked for a REMS and will likely…

    Published on 10/23/2014
  • COMPANY NEWS: J&J to launch Texas incubator

    Johnson & Johnson (NYSE:JNJ) announced plans to open the fourth incubator in its J-Labs network, formerly known as Janssen Labs, within the new Innovation Institute at Texas Medical Center in Houston. J-Labs @ TMC, a 30…

    Published on 10/23/2014
  • COMPANY NEWS: Bavarian Nordic gains on J&J Ebola deal

    Bavarian Nordic A/S (CSE:BAVA) gained DKK36.50 (24%) to DKK186.50 after the Crucell Holland B.V. unit of Johnson & Johnson (NYSE:JNJ) paid $25 million up front to license exclusive, worldwide rights to Ebola vaccine MVA…

    Published on 10/22/2014
  • COMPANY NEWS: Biogen falls on Tecfidera miss

    Biogen Idec Inc. (NASDAQ:BIIB) fell $17.70 (5%) to $309.07 on Wednesday after reporting that Tecfidera dimethyl fumarate revenues were $787 million in 3Q14, short of the $800 million consensus estimate.U.S. sales were $…

    Published on 10/22/2014

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993